SCHEMBL22734543

SCHEMBL22734543

O=C(NN1CCOc2ccccc21)c1cnc2c(-c3cc(Cl)cc(Cl)c3)cncc2c1N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ F10 P00742 1/20 0.37
▸ SSTR2 P30874 3/20 0.37
▸ KCNH2 Q12809 2/20 0.37
▸ SCN2A Q99250 1/20 0.36
▸ SCN10A Q9Y5Y9 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.35
▸ PKM P14618 1/20 0.34
▸ GPBAR1 Q8TDU6 1/20 0.34
▸ POLB P06746 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ TP53 P04637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29440697 1.00 KMT2A (0.41) KMT2AMEN1F10SSTR2KCNH2
SCHEMBL22734534 0.91 KMT2A (0.42) KMT2AMEN1F10NPSR1PKM
SCHEMBL29440692 0.88 KMT2A (0.40) KMT2AMEN1F10SCN2ASCN10A
SCHEMBL22734632 0.88 KMT2A (0.40) KMT2AMEN1F10SCN2ASCN10A
SCHEMBL22734566 0.87 KMT2A (0.38) KMT2AMEN1F10SSTR2KCNH2
SCHEMBL29440696 0.87 KMT2A (0.38) KMT2AMEN1F10SSTR2KCNH2
SCHEMBL22764080 0.86 MEN1 (0.38) KMT2AMEN1PKMPOLBCYP1A2
SCHEMBL22734544 0.86 KMT2A (0.41) KMT2AMEN1F10SCN2ASCN10A
SCHEMBL22734600 0.86 KMT2A (0.41) KMT2AMEN1F10NPSR1PKM
SCHEMBL29440722 0.86 KMT2A (0.41) KMT2AMEN1F10SCN2ASCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448391-B2 Bicyclic derivatives for treating endoparasites ELANCO TIERGESUNDHEIT AG (CH) 2025-10-21 — — US claimed
US-20240360116-A1 BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG (SZ) 2024-10-31 — — US claimed
CN-116888124-A Bicyclic derivatives 礼蓝动物保健有限公司 2023-10-13 — — CN claimed
US-20220242857-A1 BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES ELANCO TIERGESUNDHEIT AG (CH) 2022-08-04 — — US claimed
CN-114206860-A Bicyclic derivatives for the treatment of endoparasites 礼蓝动物保健有限公司 2022-03-18 — — CN claimed
US-20200385398-A1 NEW BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG 2020-12-10 — — US claimed
WO-2020247747-A1 BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES ELANCO TIERGESUNDHEIT AG (CH) 2020-12-10 — — WO claimed
US-12448391-B2 Bicyclic derivatives for treating endoparasites ELANCO TIERGESUNDHEIT AG (CH) 2025-10-21 — — US disclosed
US-20240360116-A1 BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG (SZ) 2024-10-31 — — US disclosed
CN-116888124-A Bicyclic derivatives 礼蓝动物保健有限公司 2023-10-13 — — CN disclosed
EP-4255911-A1 BICYCLIC DERIVATIVES Elanco Tiergesundheit AG (CH) 2023-10-11 — — EP disclosed
US-20220242857-A1 BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES ELANCO TIERGESUNDHEIT AG (CH) 2022-08-04 — — US disclosed
WO-2022117783-A1 BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG (CH) 2022-06-09 — — WO disclosed
WO-2022117783-A1 BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG (CH) 2022-06-09 — — WO disclosed
CN-114206860-A Bicyclic derivatives for the treatment of endoparasites 礼蓝动物保健有限公司 2022-03-18 — — CN disclosed
US-20200385398-A1 NEW BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG 2020-12-10 — — US disclosed
US-20200385398-A1 NEW BICYCLIC DERIVATIVES ELANCO TIERGESUNDHEIT AG 2020-12-10 — — US disclosed
WO-2020247747-A1 BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES ELANCO TIERGESUNDHEIT AG (CH) 2020-12-10 — — WO disclosed
WO-2020247747-A1 BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES ELANCO TIERGESUNDHEIT AG (CH) 2020-12-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448391-B2 Bicyclic derivatives for treating endoparasites TBXA2R, PIGS, CYCS KMT2A 2765/4885MEN1 2037/4885F10 1143/4885
US-20240360116-A1 BICYCLIC DERIVATIVES FABP3, CYCS, TNNI3 KMT2A 2925/4885MEN1 2797/4885F10 756/4885
US-20220242857-A1 BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES TBXA2R, PIGS, CYCS KMT2A 2765/4885MEN1 2037/4885F10 1143/4885
US-20200385398-A1 NEW BICYCLIC DERIVATIVES CYCS, FABP3, TNNI3 KMT2A 3657/4885MEN1 3381/4885F10 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback